A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Phase 3
Active, not recruiting
NCT03182244
| Condition | AML With FLT3 Mutation |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Astellas Pharma Inc |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 276 participants |
|---|
| Interventions | Gilteritinib, Cytarabine, Mitoxantrone, Etoposide, G-CSF |
|---|
| Start date | Oct 25, 2017 |
|---|
| Completion date | Dec 25, 2023 |
|---|
| Results posted | Jan 14, 2025 |
|---|
Summary
The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who were refractory to or had relapse after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy. In addition, this study evaluated safety as well as determined the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.
Overall Survival (OS)
From the date of randomization up to the date of death (up to approximatley 74 months) · months
| Gilteritinib | 10.3 months |
|---|
| Salvage Chemotherapy | 5.4 months |
|---|
| p-value | 0.00152 |
|---|
| Hazard Ratio (HR) | 0.612 (95% CI 0.451–0.832) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.